DCT

1:26-cv-00705

AbbVie Inc v. DR Reddy's Laboratories Inc

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 1:26-cv-00705, D. Del., 06/17/2026
  • Venue Allegations: Plaintiff AbbVie Inc. ("AbbVie") alleges venue is proper because Defendant Dr. Reddy's Laboratories Ltd. ("DRL Ltd.") is an Indian corporation that may be sued in any judicial district. Venue over Defendant Dr. Reddy's Laboratories, Inc. ("DRL Inc.") is alleged to be proper as it is an agent or alter ego of DRL Ltd. and has litigated other patent disputes in the district.
  • Core Dispute: Plaintiff alleges that Defendants' submission of an Abbreviated New Drug Application (ANDA) for a generic version of RINVOQ® LQ infringes patents related to processes for preparing the active ingredient upadacitinib and its solid state forms.
  • Technical Context: The technology concerns processes for preparing upadacitinib, a Janus kinase (JAK) inhibitor used in oral solutions for treating pediatric psoriatic and juvenile idiopathic arthritis.
  • Key Procedural History: This is a Hatch-Waxman action initiated by AbbVie following receipt of a Paragraph IV certification notice letter from Defendants (collectively, "DRL") regarding DRL's ANDA No. 221506. The complaint notes that DRL's notice letter did not address the '689 Patent. AbbVie alleges it brought this action within 45 days of receiving the notice, triggering a 30-month stay on FDA approval of DRL's ANDA. The complaint also details a dispute over the terms of confidential access to DRL's ANDA file.

Case Timeline

Date Event
2015-10-16 '584 Patent Priority Date
2016-06-20 '689 Patent Priority Date
2021-11-30 U.S. Patent No. 11,186,584 Issues
2025-07-22 U.S. Patent No. 12,365,689 Issues
2026-05-08 DRL sends Paragraph IV Notice Letter to AbbVie
2026-06-17 Complaint Filing Date
2031-04-26 RINVOQ® LQ orphan drug exclusivity expiration

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 11,186,584 - "Processes for the Preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof"

  • Patent Identification: U.S. Patent No. 11,186,584, "Processes for the Preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof," issued November 30, 2021.

The Invention Explained

  • Problem Addressed: The patent's background section describes a need for solid-state forms of the active compound, upadacitinib ("Compound 1"), that possess acceptable properties for large-scale preparation and inclusion in pharmaceutical formulations, such as chemical and thermal stability, solubility, and hygroscopicity '584 Patent, col. 2:6-22 The patent also notes that previously known preparation processes involved hazardous reagents '584 Patent, col. 2:23-28
  • The Patented Solution: The patent discloses specific crystalline and amorphous solid-state forms of upadacitinib and its salts, along with processes to prepare them '584 Patent, abstract These forms and processes are designed to provide an acceptable balance of properties for manufacturing and formulation, avoiding the use of hazardous materials '584 Patent, col. 2:6-28 For example, FIG. 1A details a manufacturing process to produce an amorphous freebase form of the compound via a crystalline hydrate intermediate '584 Patent, FIG. 1A
  • Technical Importance: The development of stable, manufacturable solid forms of an active pharmaceutical ingredient is a critical step in creating reliable, safe, and effective oral dosage forms for commercial distribution '584 Patent, col. 2:10-22

Key Claims at a Glance

The complaint alleges infringement of "one or more claims" of the '584 Patent without specifying them Compl. ¶45 As the accused product is an oral solution, the composition claims are particularly relevant.

  • Independent Claim 16:
    • A pharmaceutical composition comprising Amorphous Freebase of Compound 1,
    • or a pharmaceutically acceptable salt thereof,
    • and a pharmaceutically acceptable carrier.

The complaint reserves the right to assert other claims Compl. ¶45

U.S. Patent No. 12,365,689 - "Processes for the Preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof"

  • Patent Identification: U.S. Patent No. 12,365,689, "Processes for the Preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof," issued July 22, 2025.

The Invention Explained

  • Problem Addressed: The patent background notes the need for safe and effective treatments for pediatric patients with certain inflammatory diseases, for whom tablet formulations may be unsuitable '689 Patent, col. 2:15-18 This creates a need for formulations, such as liquid solutions, that provide appropriate dosing and plasma exposure in children '689 Patent, col. 2:25-33
  • The Patented Solution: The patent discloses methods of treating juvenile idiopathic arthritis by administering upadacitinib according to specific weight-based dosing regimens, which may be delivered via a stable liquid pharmaceutical composition '689 Patent, abstract '689 Patent, claim 4 The invention aims to provide pediatric patients with plasma exposures comparable to adult doses known to be efficacious '689 Patent, col. 2:25-33 FIG. 14A shows plasma concentration curves for a low-dose regimen in children aged 6 to <12 years '689 Patent, FIG. 14A
  • Technical Importance: Establishing safe and effective weight-based dosing regimens for liquid formulations is essential for treating pediatric populations who cannot swallow solid pills, thereby expanding access to therapy '689 Patent, col. 2:15-24

Key Claims at a Glance

The complaint alleges infringement of "one or more claims" of the '689 Patent without specifying them Compl. ¶67 Given the accused product is an oral solution for pediatric patients, method of treatment claims are particularly relevant.

  • Independent Claim 4:
    • A method for treating polyarticular course juvenile idiopathic arthritis (pcJIA) in a pediatric patient,
    • the method comprising administering a therapeutically effective amount of upadacitinib to the pediatric patient, wherein:
    • if the pediatric patient has a body weight in a range from about 10 kg to less than about 20 kg, administering upadacitinib twice daily at a dose of 3 mg each (3 mg BID);
    • if the pediatric patient has a body weight in a range from about 20 kg to less than about 30 kg, administering upadacitinib twice daily at a dose of 4 mg each (4 mg BID); and
    • if the pediatric patient has a body weight of about 30 kg or greater, administering upadacitinib twice daily at a dose of 6 mg each (6 mg BID), or once daily at a dose of 15 mg (15 mg QD).

The complaint reserves the right to assert other claims Compl. ¶67

III. The Accused Instrumentality

Product Identification

The accused instrumentality is DRL's proposed generic version of AbbVie's RINVOQ® LQ 1 mg/mL oral solution, identified as "DRL's ANDA Product" and filed under ANDA No. 221506 Compl. ¶1 Compl. ¶15

Functionality and Market Context

The complaint alleges that DRL's ANDA Product is a 1 mg/mL oral solution containing the active ingredient upadacitinib Compl. ¶1 Compl. ¶3 It is intended for the treatment of pediatric patients with active psoriatic arthritis and polyarticular juvenile idiopathic arthritis Compl. ¶2 AbbVie alleges that DRL intends to manufacture, market, and sell the product throughout the United States upon FDA approval, which would directly compete with and displace sales of AbbVie's branded RINVOQ® LQ product Compl. ¶17 Compl. ¶26

IV. Analysis of Infringement Allegations

The complaint does not provide a claim chart or a detailed technical theory of infringement for either patent-in-suit. It makes conclusory allegations that DRL's submission of its ANDA constitutes an act of infringement under 35 U.S.C. § 271(e)(2)(A) and that future commercial activity would infringe under other subsections of § 271 Compl. ¶¶46-48 Compl. ¶¶68-70 No probative visual evidence provided in complaint.

  • '584 Patent Infringement Allegations

    • The complaint does not provide sufficient detail for a claim chart analysis. The core of the dispute will depend on the physical and chemical properties of the upadacitinib active pharmaceutical ingredient (API) contained within DRL's ANDA Product.
    • Identified Points of Contention:
      • Scope Questions: The primary dispute will likely concern whether the API in DRL's product falls within the scope of the asserted composition claims. For a claim to the "Amorphous Freebase" (e.g., Claim 16), a key question is whether DRL's API is, in fact, that specific solid-state form.
      • Technical Questions: The case will require factual evidence, likely obtained through discovery of DRL's ANDA, to characterize DRL's API using techniques such as Powder X-ray Diffraction (PXRD) or Differential Scanning Calorimetry (DSC), which are used in the '584 patent to define its claimed forms '584 Patent, e.g., figs. 2A-3J The central technical question is whether DRL's API exhibits the characteristics of a claimed solid form.

  • '689 Patent Infringement Allegations

    • The complaint does not provide sufficient detail for a claim chart analysis. Infringement of the asserted method of treatment claims will depend on the intended uses described in the proposed label for DRL's ANDA Product.
    • Identified Points of Contention:
      • Scope Questions: For a method claim like Claim 4, a central question is whether the term "administering a therapeutically effective amount" is limited to the exact weight-based dosing regimens recited in the claim, or if it could be construed more broadly.
      • Technical Questions: The key infringement question is factual: Does DRL's proposed product label instruct or encourage physicians to prescribe the generic oral solution to pediatric pcJIA patients according to the specific weight-based dosing schedules outlined in Claim 4? If the label's instructions differ, the court may need to consider whether the differences are insubstantial for a potential finding of infringement under the doctrine of equivalents.

V. Key Claim Terms for Construction

  • '584 Patent: "Amorphous Freebase of Compound 1"

    • The Term: Amorphous Freebase of Compound 1 (from representative Claim 16)
    • Context and Importance: The definition of this term is fundamental to the infringement analysis of the '584 patent. Practitioners may focus on this term because DRL could argue that its API is either a different, non-infringing polymorph or that it does not possess the specific characteristics required to be the claimed "Amorphous Freebase," thereby avoiding infringement.
    • Intrinsic Evidence for Interpretation:
      • Evidence for a Broader Interpretation: The specification provides a general definition of "amorphous" as a state that "lacks long range order at the molecular level" '584 Patent, col. 29:16-24 AbbVie may argue the term should be given this plain and ordinary meaning.
      • Evidence for a Narrower Interpretation: The specification provides detailed characterization data for the amorphous form, including specific PXRD patterns (FIGS. 2A-2B), TGA thermograms (FIGS. 4A-4B), and a DSC thermogram showing a glass transition onset at about 119°C (FIG. 5A). DRL may argue that the term should be limited to an amorphous material exhibiting these specific physical properties.

  • '689 Patent: "administering a therapeutically effective amount"

    • The Term: administering a therapeutically effective amount (from representative Claim 4)
    • Context and Importance: This term is critical because it is explicitly defined within the claim by specific weight-based dosing regimens. Practitioners may focus on this term because if DRL's proposed label recommends different dosing, it could form the basis of a non-infringement argument.
    • Intrinsic Evidence for Interpretation:
      • Evidence for a Broader Interpretation: The patent's abstract and summary broadly discuss providing "therapeutically effective" amounts of upadacitinib to pediatric patients to achieve "comparable plasma exposure" to adult doses '689 Patent, abstract '689 Patent, col. 2:25-33 This could support an argument that any dosing achieving such exposure is "therapeutically effective."
      • Evidence for a Narrower Interpretation: Claim 4 itself explicitly defines the "therapeutically effective amount" through a series of "wherein" clauses that tie specific doses (e.g., 3 mg BID, 4 mg BID) to specific patient weight categories '689 Patent, claim 4 This provides strong intrinsic evidence that the term is limited to the specific regimens recited in the claim.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges that DRL will actively induce and/or contribute to the infringement of both patents Compl. ¶40 Compl. ¶70 For the '689 patent, this allegation is based on the premise that DRL's proposed product label will instruct medical professionals and patients to use the ANDA Product in an infringing manner Compl. ¶70
  • Willful Infringement: The complaint does not use the term "willful infringement" but alleges that DRL has "actual and constructive notice" of the patents Compl. ¶49 Compl. ¶71 It further alleges that DRL's notice letter "lacks any sufficient contention" that the patents are invalid or not infringed, which it claims "renders this case 'exceptional'" under 35 U.S.C. § 285, entitling AbbVie to attorneys' fees Compl. ¶51 Compl. ¶73

VII. Analyst's Conclusion: Key Questions for the Case

  • A primary factual question will be one of API characterization: What is the solid-state form of the upadacitinib in DRL's ANDA Product, and does it meet the structural and characteristic limitations of the composition claims of the '584 patent? This determination will likely require extensive expert analysis of discovery materials from DRL's ANDA.
  • A central legal and factual question for the '689 patent will be one of label-based infringement: Does the proposed product label for DRL's ANDA Product instruct or encourage administration to pediatric patients according to the specific, multi-tiered weight-based dosing regimens recited in the asserted method of treatment claims?
  • A key procedural question is the adequacy of pre-suit conduct: The court will need to address AbbVie's allegations regarding DRL's purportedly "unreasonable" offer of confidential access to its ANDA and the alleged deficiencies in its notice letter, which may influence early discovery motions and could factor into a later determination of whether the case is "exceptional."
Loading Complaint